骨髓间充质干细胞移植治疗心肌梗死的研究进展

Progress in treatment of myocardial infarction with transplantation of bone marrow mesenchymal stem cells

溶栓、经皮冠状动脉介入治疗及常规药物治疗可挽救许多急性心肌梗死患者的生命,但不能从根本上恢复心肌细胞数量。骨髓间充质干细胞(BM-MSCS)是骨髓中一种具有多向分化潜能的细胞,可被诱导分化为心肌样细胞,改善梗死区的血液供应及心肌重构,为心肌梗死的治疗带来了新的希望。本文就BM-MSCS移植治疗心肌梗死的方式,移植的时机及临床应用等方面作一综述。

Although many patients with acute myocardial infarction can be saved by treatment of thrombolysis,percutaneous coronary intervention and conventional drugs,these approaches cannot restore the number of myocardial cells.Bone marrow mesenchymal stem cells（BM-MSCS） with their multidirectional differentiation potentials can be induced to differentiate into cardiomyocyte-like cells,improve circulation in the infarct area and prevent myocardium from remodeling.The manner,timing and clinic application of BM-MSCS transplantation for myocardial infarction are reviewed.